Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors

A Phase I Trial Of Oral Calcitriol [1,25-(OH)2D3] And Paclitaxel In Advanced Solid Tumors


Hauptsponsor: University of Pittsburgh

Mitarbeiter: National Cancer Institute (NCI)

Quelle University of Pittsburgh
Kurze Zusammenfassung

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug.

PURPOSE: Phase I trial to study the effectiveness of combining calcitriol with paclitaxel in treating patients who have advanced solid tumors.

detaillierte Beschreibung


- Determine the toxic effects and maximum tolerated dose of calcitriol when combined with paclitaxel in patients with advanced solid tumors.

- Determine the effect of administration of calcitriol on the pharmacokinetics of paclitaxel in these patients.

- Determine the effect of administration of paclitaxel on the pharmacokinetics of calcitriol in these patients.

OUTLINE: This is a dose-escalation study of calcitriol.

During course 1, patients receive oral calcitriol daily on days 1-3 of weeks 1-6 and paclitaxel IV over 1 hour on day 1 of week 1 and day 3 of weeks 2-6. During course 2 and subsequent courses, patients receive oral calcitriol daily on days 1-3 and paclitaxel IV over 1 hour on day 3 of weeks 1-6. Treatment continues every 8 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of calcitriol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose giving an estimated probability of dose-limiting toxicity of no more than 0.30.

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

Gesamtstatus Completed
Anfangsdatum June 1998
Fertigstellungstermin June 2005
Primäres Abschlussdatum June 2005
Phase Phase 1
Studientyp Interventional
Einschreibung 45

Interventionsart: Dietary Supplement

Interventionsname: calcitriol

Interventionsart: Drug

Interventionsname: paclitaxel




- Histologically proven advanced cancer not curable by standard therapies

- Brain metastases allowed following definitive radiotherapy



- 18 and over

Performance status:

- ECOG 0-2

Life expectancy:

- Not specified


- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3


- Bilirubin no greater than 1.5 mg/dL

- SGOT no greater than 4 times normal


- Creatinine no greater than 2.0 mg/dL

- Calcium no greater than 10.5 mg/dL


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-barrier contraception for at least 1 week before, during, and for at least 2 weeks after study

- No active infection or serious concurrent condition

- No symptomatic peripheral neuropathy greater than grade 1


Biologic therapy:

- At least 3 weeks since prior regional or systemic biologic therapy


- At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea)

Endocrine therapy:

- Not specified


- See Disease Characteristics

- At least 3 weeks since prior radiotherapy


- Not specified

Geschlecht: All

Mindestalter: 18 Years

Maximales Alter: N/A

Gesunde Freiwillige: No

Insgesamt offiziell
Nachname Rolle Zugehörigkeit
Ramesh K. Ramanathan, MD Study Chair University of Pittsburgh
Einrichtung: University of Pittsburgh Cancer Institute
Standort Länder

United States


December 2013

Verantwortliche Partei

Art: Principal Investigator

Ermittlerzugehörigkeit: University of Pittsburgh

Vollständiger Name des Ermittlers: Laura A. Pollice

Ermittlertitel: Clinical Research Manager

Hat den Zugriff erweitert No
Bedingung Durchsuchen
Studiendesign Info

Hauptzweck: Treatment